low dose better than high dose or placebo

Trial participants receiving a low dose of ataluren did better than those receiving a placebo or high dose, additional analysis reveals

posted on April 19, 2010 - 4:35pm
PTC Therapeutics, a South Plainfield, N.J., biopharmaceutical company, has announced findings that reflect the company's closer look at a large-scale trial of its experimental drug ataluren. The additional results, presented April 16 at the American Academy of Neurology  meeting in Toronto, show that trial participants who took the lower dose of ataluren did better on a six-minute walking...

New content is being added every day. Please check back again.